PMID- 24841535
OWN - NLM
STAT- MEDLINE
DCOM- 20141110
LR  - 20211021
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 63
IP  - 8
DP  - 2014 Aug
TI  - Murine Th9 cells promote the survival of myeloid dendritic cells in cancer 
      immunotherapy.
PG  - 835-45
LID - 10.1007/s00262-014-1557-4 [doi]
AB  - Dendritic cells (DCs) are professional antigen-presenting cells to initiate 
      immune responses, and DC survival time is important for affecting the strength of 
      T-cell responses. Interleukin (IL)-9-producing T-helper (Th)-9 cells play an 
      important role in anti-tumor immunity. However, it is unclear how Th9 cells 
      communicate with DCs. In this study, we investigated whether murine Th9 cells 
      affected the survival of myeloid DCs. DCs derived from bone marrow of C57BL/6 
      mice were cocultured with Th9 cells from OT-II mice using transwell, and the 
      survival of DCs was examined. DCs cocultured with Th9 cells had longer survival 
      and fewer apoptotic cells than DCs cultured alone in vitro. In melanoma B16-OVA 
      tumor-bearing mice, DCs conditioned by Th9 cells lived longer and induced 
      stronger anti-tumor response than control DCs did in vivo. Mechanistic studies 
      revealed that IL-3 but not IL-9 secreted by Th9 cells was responsible for the 
      prolonged survival of DCs. IL-3 upregulated the expression of anti-apoptotic 
      protein Bcl-xL and activated p38, ERK and STAT5 signaling pathways in DCs. Taken 
      together, our data provide the first evidence that Th9 cells can promote the 
      survival of DCs through IL-3, and will be helpful for designing Th9 cell 
      immunotherapy and more effective DC vaccine for human cancers.
FAU - Park, Jungsun
AU  - Park J
AD  - Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for 
      Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Li, Haiyan
AU  - Li H
FAU - Zhang, Mingjun
AU  - Zhang M
FAU - Lu, Yong
AU  - Lu Y
FAU - Hong, Bangxing
AU  - Hong B
FAU - Zheng, Yuhuan
AU  - Zheng Y
FAU - He, Jin
AU  - He J
FAU - Yang, Jing
AU  - Yang J
FAU - Qian, Jianfei
AU  - Qian J
FAU - Yi, Qing
AU  - Yi Q
LA  - eng
GR  - R01 CA96569/CA/NCI NIH HHS/United States
GR  - P50 CA142509/CA/NCI NIH HHS/United States
GR  - R01 CA138398/CA/NCI NIH HHS/United States
GR  - R01 CA138402/CA/NCI NIH HHS/United States
GR  - R01 CA096569/CA/NCI NIH HHS/United States
GR  - R01 CA163881/CA/NCI NIH HHS/United States
GR  - R01 CA103978/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140520
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Interleukin-3)
RN  - 0 (Interleukin-9)
SB  - IM
MH  - Animals
MH  - Cell Communication/immunology
MH  - Cell Differentiation/immunology
MH  - Cell Survival/immunology
MH  - Coculture Techniques
MH  - Dendritic Cells/cytology/*immunology
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Interleukin-3/biosynthesis/immunology
MH  - Interleukin-9/*immunology
MH  - Male
MH  - Melanoma, Experimental/immunology/*therapy
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Signal Transduction
MH  - T-Lymphocytes, Helper-Inducer/cytology/*immunology
PMC - PMC4200484
MID - NIHMS597092
COIS- The authors declare no competing financial interests.
EDAT- 2014/05/21 06:00
MHDA- 2014/11/11 06:00
PMCR- 2014/05/20
CRDT- 2014/05/21 06:00
PHST- 2013/10/28 00:00 [received]
PHST- 2014/04/24 00:00 [accepted]
PHST- 2014/05/21 06:00 [entrez]
PHST- 2014/05/21 06:00 [pubmed]
PHST- 2014/11/11 06:00 [medline]
PHST- 2014/05/20 00:00 [pmc-release]
AID - 1557 [pii]
AID - 10.1007/s00262-014-1557-4 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2014 Aug;63(8):835-45. doi: 10.1007/s00262-014-1557-4. 
      Epub 2014 May 20.